drugset / Trial / NCT00706134

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

NCT00706134

Phase 3 Completed 756 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.

Timeline

Start
2008-05
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 75 mg
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg